Skip to content

Influence of Inhaler Compliance on the Treatment of Asthma Patients

Influence of Inhaler Compliance on the Treatment of Asthma Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06108908
Enrollment
150
Registered
2023-10-31
Start date
2019-08-14
Completion date
2024-08-31
Last updated
2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Pulmonary Disease

Brief summary

The major goal of Influence of Inhaler Compliance on the Treatment of Asthma Patients is to explore compliance rate outcome in adult asthmatic patients (20-80 years old) with mild to moderate persistent asthma according to American Thoracic Society (ATS) definition and diagnosis. The major endpoints include: 1. To increase the adherence rate of treatment by reminder intervention with correctly monitor patients' adherence rate by Asthma Supportive Kits 2. Eventually achieve best asthma care and management. All participants will use Asthma Supportive Kits for 24 weeks and return visit on week 5, 12, 24. Based on collected data, the study compares intervention and control group to see if active reminder intervention may effectively alter compliance rate, and corresponding outcomes, e.g., asthma control status, acute exacerbation events.

Detailed description

1. Upon enrollment, the all patients will be educated and equipped with asthma supportive kits, which is a electronic device attaches to an MDI medicine. 2. The asthma supportive kit registers every puff taken when the patient uses his/her MDI. The records are monitored by study nurses and calculated compliance ratio on rolling basis. 3. By enrollment, the patient is RANDOMLY assigned to Intervention and Control group. For the Intervention group in each study phases, when the given compliance ratio drops below 80% (as monitored by asthma supportive kit), the study nurse will actively engage to remind on medicine taking. For the Control group, the compliance ratio is calculated but to active engagement is applied. 4. All the patients adheres with regular asthma treatment mechanism, regardless to group assigned.

Interventions

BEHAVIORALReminder

1\. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.

Sponsors

Taipei Medical University
CollaboratorOTHER
Taipei Medical University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Adult asthmatic patients (20-80 years old) 2. With mild to moderate persistent asthma according to ATS definition and diagnosis 3. Willing to use Budesonide+Formoterol. 4. Adequately use inhaler 5. Without evident intentional non-adherence 6. Agree asthma is a common and potentially serious chronic disease 7. Willing to sign Informed Consent Form

Exclusion criteria

1. Inadequately use inhaler 2. Disagree asthma is a common and potentially serious chronic disease 3. With uncontrolled systemic diseases, such as hypertension, heart failure, renal failure, de-compensated liver cirrhosis, etc.;

Design outcomes

Primary

MeasureTime frameDescription
compliance ratio28 dayCompliance Ratio: 1. the Compliance Ratio evaluates the ratio of days which the patient is taking equal (or greater than) puffs of medicine as instructed by physician with the past 28-days. 2. the outcome ratio ranges from 0% (none of days is taking correct amount) to 100% (all past 28 days were taking correct amount).
Asthma Control Test Score28 dayAsthma Control Test (ACT) Score: 1. the ACT is a patient self-administrated tool for identifying those with poorly controlled asthma; 2. the test includes 5 items to recall past 4-week symptoms and daily functioning; 3. The scores range from 5 as poorly controlled to 25 as completely controlled of asthma

Countries

Taiwan

Contacts

Primary ContactHan-Pin KUO
hpk8828@gmail.com+886975368066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026